Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug reimbursement
Pharma
Madrigal builds launch infrastructure for MASH drug Rezdiffra
Despite a reimbursement hurdle from the VA, Madrigal is still targeting 80% commercial coverage for its MASH drug Rezdiffra by year-end.
Angus Liu
May 7, 2024 11:56am
Bluebird pushes Lyfgenia's US coverage to nearly 200M people
Jan 4, 2024 11:15am
BMS, China reimbursement update, CAR-T hold—Fierce Pharma Asia
Dec 15, 2023 5:15am
Bluebird signs first coverage deal for SCD gene therapy Lyfgenia
Dec 14, 2023 11:04am
NICE poised to reject Enhertu in HER2-low breast cancer
Sep 27, 2023 10:51am
Amgen fights FTC's request for injunction against Horizon buyout
Aug 24, 2023 11:12am